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Background: Cyclic nucleotide specific phosphodiesterases (PDEs) are essential enzymes in many parasitic protozoa and
represent important new drug targets.
Results: The crystallographic structure and enzymatic properties of Trypanosoma cruzi phosphodiesterase C (TcrPDEC) have
been determined.
Conclusion: A parasite-specific pocket next to the TcrPDEC active site might allow designing parasite-specific inhibitors.
Significance: The findings highlight the potential of PDEs as anti-parasite drug targets.
Trypanosoma cruzi phosphodiesterase C (TcrPDEC) is a
potential new drug target for the treatment of Chagas disease
but has not been well studied. This study reports the enzymatic
properties of various kinetoplastid PDECs and the crystal struc-
tures of the unliganded TcrPDEC1 catalytic domain and its
complex with an inhibitor. Mutations of PDEC during the
course of evolution led to inactivation of PDEC inTrypanosoma
brucei/Trypanosoma evansi/Trypanosoma congolense, whereas
the enzyme is active in all other kinetoplastids. The TcrPDEC1
catalytic domain hydrolyzes both cAMP and cGMPwith aKm of
23.8 M and a kcat of 31 s1 for cAMP and aKm of 99.1 M and a
kcat of 17 s1 for cGMP, thus confirming its dual specificity. The
crystal structures show that the N-terminal fragment wraps
around the TcrPDEC catalytic domain andmay thus regulate its
enzymatic activity via direct interactionswith the active site res-
idues. A PDE5 selective inhibitor that has an IC50 of 230 nM for
TcrPDEC1binds toTcrPDEC1inanorientationopposite to thatof
sildenafil. This observation, together with the screen of the inhibi-
tory potency of human PDE inhibitors against TcrPDEC, implies
that the scaffold of some human PDE inhibitors might be used as
the startingmodel fordesignofparasitePDE inhibitors.The struc-
tural study also identified a unique parasite pocket that neighbors
the active site andmay thus be valuable for the design of parasite-
specific inhibitors.
Chagas disease, also known as American trypanosomiasis, is
a tropical parasitic disease that currently affects 10 million
people in Latin America (1, 2). The disease is caused by Trypa-
nosoma cruzi, a kinetoplastid protozoan that is delivered by
blood-sucking bedbugs such as Rhodnius prolixus (3). After an
acute phase of infection, with a mortality rate of 10%, the
infection can persist without overt clinical symptoms for 20–30
years. Although a considerable proportion of the cases never
progress beyond this initial stage, many patients finally suc-
cumb to the slow but inexorable destruction of themusculature
of heart, intestines, and esophagus (2).
In the kinetoplastids, including T. cruzi, differentiation and
cell cycle regulation are under the control of cyclic nucleotide
signaling (4–6), in which phosphodiesterases (PDEs)4 are the
sole enzymes that decompose cyclic nucleotides. PDE activity is
also involved in the osmoregulation of cell volume after
hypoosmotic shock (7, 8). Disruption of cyclic nucleotide sig-
naling has been shown to eliminate Trypanosoma brucei infec-
tion from the host (9). In this context, PDE inhibitors might
constitute a new class of potent drug candidates for protozoal
infections. In T. cruzi, several cyclic nucleotide-specific PDEs
have already been characterized (10–14), and a number of
TcrPDE inhibitors have been reported (15).
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The genomes of kinetoplastids, including T. cruzi, encode
four PDE families, termedTcrPDEA, B, C, andD (16) (Fig. 1), in
contrast to the human genome, which contains 21 PDE genes
categorized into 11 families. TcrPDEA, C, andD each consist of
a singlemember, whereas TcrPDEB contains two highly similar
and tandemly arranged genes. TcrPDEA is a cAMP-specific
PDE with a high Km and is not inhibited by isobutylmethylxan-
thine, papaverine, or theophylline (10). The highly similar
TcrPDEB1 and TcrPDEB2 are cAMP-specific and contain two
GAF domains upstream of their catalytic domains (11, 14, 17).
TcrPDEC contains a FYVE-type domain (18) at its N terminus
and was shown to hydrolyze both cAMP and cGMP with simi-
larKm values (13). This observation is supported by recentwork
of Docampo and co-workers (15) but is in contrast to the claim
that TcrPDEC is cAMP-specific (11). TcrPDEC activity has
been implicated in osmoregulation (8, 12, 15). TcrPDED and its
orthologs in other kinetoplastids have so far not been experi-
mentally investigated.
Although Chagas disease and its causative agent T. cruzi
were discovered 100 years ago (2), there are only a handful of
clinically useful drugs at present, and no vaccine is available
(19–22). Worse still, all current drugs cause severe side effects,
and their use is hampered by drug resistance (23), emphasizing
an urgent need for the discovery of new and more effective
drugs for the treatment of Chagas disease (24). In this study, we
report the enzymatic properties of various kinetoplastid
PDECs, and the crystal structures of the unliganded TcrPDEC1
and its complex with the inhibitor wyq16 (5-(2-ethoxy-5-(N-
isopropyloxycarbonyl-aminosulfonyl)-1-methyl-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-7(6H)-one) (Fig. 2). These results
provide guidelines for the design of TcrPDEC inhibitors for the
treatment of Chagas disease.
EXPERIMENTAL PROCEDURES
Cloning of Kinetoplastid PDEC Genes and Expression in Sac-
charomyces cerevisiae—The entire PDEC coding sequences of
five kinetoplastid species were amplified by PCR (Expand High
FidelityPCR system; RocheApplied Science) and clonedusing
a TA cloning kit (TOPO TA cloning kit from Invitrogen or
pGEM-T easy vector system from Promega). PCR amplifica-
tion of the respective DNA fragments was performed using the
following primer pairs: oPREM-for1 5-CAGTCGACATATGG-
TGTGCTACGACGGTTC-3 and oPREM-rev7b 5-GAGGAT-
CCTCAAGGACCCACCGACGC-3 for T. brucei TbrPDEC
(genomic DNA of procyclic strain 427), oTconPDE4-for 5-
CAGTCGACATATGTGTAAATACCTTAGCACC-3 and
oTconPDE4-rev 5-CTGGATCCCTACTTTGCCAACAAC-
GTTGCC-3 for Trypanosoma congolense TcoPDEC (genomic
DNA of strain Savannah ALME/CAM), oTviPDEC-f
5-GCACATATGTACAGTTCTAAGGAGTCGCAC-3 and
oTviPDEC-r 5-GCAGATCTTTATCTGTCCAAGAATAA-
TCCTGAG-3 for Trypanosoma vivax TviPDEC (genomic
DNA of strain Y486), oTcPDE4-for 5-CAGTCGACATATG-
TCGGAGGACGCTGGGCTTC-3 and oTcPDE4-r 5-CGT-
GGATCCTCAGCACTGCGTCAACAGAGTG-3 for T. cruzi




of the cloned PCR products were verified by sequencing.
For expression in S. cerevisiae, the entire PDEC open reading
frameswere subcloned from theTAvectors into two variants of
the yeast expression vector pLT1 (13) using the restriction
enzymes SalI/BamHI or NdeI/BglII (sites are indicated by bold
letters in the primer sequences). One pLT1 variant directs the
expression of the kinetoplastid protein alone, whereas the other
adds an N-terminal hemagglutinin tag to allow detection of the
recombinant protein. Transformation of the constructs into
the PDE-deficient S. cerevisiae strain PP5 (MATa leu2-3 leu2-
112 ura3-52 his3-532 his4 cam pde1::URA3 pde2::HIS3) was
carried out as described previously (25).
Yeast Cell Lysis—Yeast cell lysates were prepared as previ-
ously described (26). Briefly, yeast was grown in SC-Leu
medium to end log phase, collected by centrifugation, and
resuspended in the original volume of prewarmed YPD. The
FIGURE 1. The PDE genes of the kinetoplastids. A, domain structures of the
four PDE families that are present in all currently sequenced kinetoplastid
genomes (T. brucei, T. cruzi, T. vivax, T. congolense, T. evansi, Crithidia fascicu-
lata, Leishmania tarentolae, L. major, L. braziliensis, L. mexicana, and L. infan-
tum). B, domain structures of PDECs from various kinetoplastid species. Cross-
hatched bars, FYVE-type domains; gray bars, coiled-coil regions; black bars,
catalytic domains.
FIGURE 2. Chemical structures of sildenafil and wyq16.
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culture was incubated for an additional 3.5 h to maximize pro-
tein expression. The cells were then washed twice in H2O, and
the pelleted cell was snap-frozen in liquid nitrogen and stored
at 70 °C. The pellet was thawed on ice and resuspended in an
equal volume of ice-cold extraction buffer (50 mM Hepes, pH
7.5, 100 mM NaCl, 1 Complete protease inhibitor mixture
without EDTA (RocheApplied Science)). Cell lysates were pro-
duced by mechanical disruption with glass beads (0.45–0.50
mm) using a FastPrep FP120 high speed reciprocating device
(four times for 45 s at setting 4). The lysate was cleared by
centrifugation and frozen for later use.
Subcloning of Catalytic Domain TcrPDEC1 in Escherichia
coli and Protein Purification—A pair of primers that contain
the restriction sites NheI and EcoRI was designed for the sub-
cloning. The DNA sequence encoding the catalytic domain of
TcrPDEC1 (amino acids 270–614) was amplified by PCR. The
amplified TcrPDEC1 fragment and the expression vector
pET28a were digested with the restriction enzymes, purified by
agarose gel, and ligated with T4 DNA ligase. The resultant
plasmid pET-PDEC1 was transferred into E. coli strain
BL21(CodonPlus) (Agilent Technologies) for expression. The
E. coli cell carrying pET-PDEC1 was grown in LB medium at
37 °C to an absorption ofA600  0.7, and then 0.1mM isopropyl
-D-thiogalactopyranoside was added to further grow at 15 °C
for 24 h. The harvested cells were suspended in a lysis buffer (3
ml/gram) consisting of 20 mM Tris-HCl, pH 7.5, 300 mMNaCl,
and 15 mM imidazole and disrupted by French Press with
1500 p.s.i. After centrifugation at 15,000 rpm for 20 min, the
supernatant was loaded into a nickel-nitrilotriacetic acid col-
umn (Qiagen). The nickel-nitrilotriacetic acid column was
washedwith300ml of lysis buffer and then100ml of buffer
of 20mMTris-HCl, pH 8,0, 50mMNaCl, 15mM imidazole. The
TcrPDEC1proteinwas eluted by using 20mMTris-HCl, pH7.5,
50 mM NaCl, and 250 mM imidazole. The N-terminal His6-
tagged TcrPDEC1 was cleaved by thrombin, and the protein
was further purified by Q-Sepharose with three buffers of 20
mM Tris-HCl, pH 7.5, 1 mM 2-mercaptoethanol, 1 mM EDTA,
andNaCl at 0.1, 0.2, and 0.3 M. Finally, a Sephacryl S300 column
(GE Healthcare) was used to remove aggregated protein and to
switch to a buffer consisting of 20 mM Tris-HCl, pH 7.5, 1 mM
2-mercaptoethanol, 1 mM EDTA, 50 mM NaCl. A typical puri-
fication yielded10mg of TcrPDEC1with a purity95% from
a 2-liter cell culture. Protein concentrations were calculated
from extinction coefficients by the program ProtParam, and an
A280 of 0.701 M1 cm1 was equal to 1 mg/ml of TcrPDEC1
(residues 270–614).
Selenomethionyl-substituted TcrPDEC1was prepared using
the protocol described by Doublie (27). The E. coli cell was cul-
tured in the M9 minimal medium that was supplemented with
the following amino acids: 100 mg/ml Lys, 100 mg/ml Thr, 100
mg/ml Phe, 50 mg/ml Leu, 50 mg/ml Ile, 50 mg/ml Val, and 50
mg/ml selenomethionine. The protocol for purification of sel-
enomethionyl-substituted TcrPDEC1 was the same as that
used for purification of the wild-type TcrPDEC1.
Enzymatic Properties—Enzymatic activities were assayed
using [3H]cAMP and [3H]cGMP as substrates, as previously
reported (28). The catalytic domain of TcrPDEC1 was incu-
bated at 24 °C for 15 min with a reaction mixture of 20 mM
TrisHCl, pH 7.5, 10 mM MgCl2, 1 mM DTT, [3H]AMP, or
[3H]cGMP (20,000–40,000 cpm/assay, 20 nM in a 100-l
assay), and appropriate concentrations of nonradiolabeled
cAMP or cGMP. The reaction was terminated by the addition
of 0.2 M ZnSO4. The reaction product [3H]AMP or [3H]GMP
was precipitated out by the addition of 0.25MBa(OH)2, whereas
unreacted [3H]AMP or [3H]cGMP remained in the superna-
tant. After centrifugation, the radioactivity in the supernatant
was measured in a liquid scintillation counter. The turnover
was controlled at hydrolysis of 15–30% substrate under a suit-
TABLE 1
Statistics of diffraction data and structure refinement
Native TcrPDEC1 TcrPDEC1-wyq16 Se-TcrPDEC1
Data collection
Space group P41212 P41212 P41212
Unit cell (a, c) (Å) 130.3, 388.9 131.1, 394.7 131.2, 395.1
Resolution range (Å) 30.0–2.0 30.0–2.33 30.0–2.33
Unique reflections 219, 103 146, 141 278, 015
Fold of redundancy 8.9 27.2 14.3
Completeness (%) 94.4 (100.0)a 98.7 (100.0)a 98.6 (100.0)a
Average I/ 8.4 (4.2)a 8.3 (5.0)a 5.8 (4.8)a
Rmerge 0.101 (0.61)a 0.125 (0.60)a 0.156 (0.80)a
Structure refinement
Rfactor 0.216 0.227
Rfree 0.246 (10%)b 0.267 (10%)b
Resolution range (Å) 30.0–2.0 30.0–2.33
Reflections 205, 388 140, 293
Root mean square deviation
For bond length 0.0055 0.0089
For angle 1.11o 1.55o
Average B factor (Å2)
Protein 30.1 (20520)c 32.5 (20633)c
wyq16 37.7 (264)c
Water 27.0 (975)c 28.1 (874)c
Zn2 23.2 (8)c 27.4 (8)c
Mg2 22.1 (8)c 23.6 (8)c
No. of molecules in the asymmetric unit 8 8
No. of disallowed residues in Ramachandran plot 0 0
a The numbers in parentheses are for the highest resolution shells, 2.07–2.0 for the native and 2.41–2.33 Å for the wyq16 complex.
b 10% of reflections were omitted in the refinement for calculation of Rfree.
c The number of atoms in the crystallographic asymmetric unit.
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able enzyme concentration. Nine concentrations of cAMP or
cGMP in a range of 0.04–800 M were used to obtain the
kinetic parameters.
Enzymatic properties were analyzed by steady state kinetics,
as shown in the form ofMichealis-Menten’s equation (29). The
nonlinear regression (GraphPad Prism 5.0) was applied to
obtain the values of Km, Vmax, and kcat. For measurement of
IC50, eight concentrations of inhibitors were used at a substrate
concentration of 1/10 Km and a suitable enzyme concentra-
tion. All of the measurements were repeated three times.
For screening potential inhibitors, a set of human PDE inhib-
itors was dissolved in Me2SO as 10 mM stocks and used at a
concentration of 100 M in the PDE assay. The assay was con-
ductedwith lysates of yeast expressing full-lengthTcrPDEC1 as
described (26). 1 M cAMPwas used as substrate, and no more
than 20% substrate was hydrolyzed in all reactions. TheMe2SO
concentration in the final assay solutions never exceeded 1%,
and appropriate control reactions with Me2SO alone were
always included.
Crystallization and Structure Determination of TcrPDEC1—The
catalytic domain of the unliganded TcrPDEC1 (270–614) and
its complex with wyq16 was crystallized by vapor diffusion
against awell buffer of 20%PEG3350, 0.4M sodium formate, 0.2
M guanidine, 0.1 M MES, pH 6.5, at 4 °C. The hanging drops
contain 2 l of protein (10 mg/ml) and 2 l of well buffer. The
inhibitor complex was prepared by incubation of TcrPDEC1
with 2 mM wyq16 (0.1 M stock in Me2SO) for 1 h on ice before
crystallization. Diffraction data were collected on Beamline
X29 at Brookhaven National Laboratory (Table 1) and pro-
cessed by the program HKL (30). The crystal of the unliganded
TcrPDEC1 has the space group P41212 with cell dimensions of
a  b  130.3 Å and c  388.9 Å. The TcrPDEC1-wyq16 com-
plex was crystallized in the same space group but slightly differ-
ent cell dimensions of a  b  131.1 Å and c  394.9 Å.
The structure of TcrPDEC1 was solved by the single-wave-
length anomalous diffraction method (31), using a selenome-
thionine derivative of the TcrPDEC1 catalytic domain. The ini-
tial positions of selenium atoms were located by program
SHELX-97 (32) and refined to yield a figure ofmerit of 0.43. The
map was subsequently modified by program PHENIX (33) and
clearly revealed the protein trace (supplemental Fig. S1). The
structure of TcrPDEC1 in complex with inhibitor wyq16 was
solved by the molecular replacement program AMoRe (34),
using the native TcrPDEC1 structure as the initial model. The
phases from the molecular replacement were improved by the
density modification package of CCP4. The structures were
rebuilt by the programO (35) and refined by the program CNS
(36).
RESULTS AND DISCUSSION
PDEC Is Inactive in Some Kinetoplastid Species—Sequence
analysis of the kinetoplastid genomes revealed the presence of a
PDEC gene in each of these genomes: T. cruzi (Tc00.
1047053506697.20, chromosome 36-S), T. brucei (Tb927.
3.3070, chromosome 3), and Trypanosoma evansi.5 The
sequences of TbrPDEC and TevPDEC differ by only three
amino acids, one of which is within the catalytic domain (Ala-
598 of T. brucei versus Val-599 in T. evansi.). T. congolense
TcoPDEC gene was sequenced from two different Savannah
strains, ALME/CAM and CARBA/CAM. These two sequences
were identical but differed from the TcIL3000.3.1980 (chromo-
some 3) reference sequences deposited in GeneDB (42/2851
nucleotides, 13/950 amino acids): T. vivax (chromosome 3),6
Leishmania infantum (LinJ.29.2790, chromosome 29), Leish-
mania mexicana (LmxM08_29.2680, chromosome 29), Leish-
mania braziliensis (LbrM.29.2740, chromosome 29), and
L. major (LmjF.29.2680, chromosome 29). Unexpectedly, the
PDEC sequence alignment (supplemental Fig. S2) showed that
two histidines conserved in all class 1 PDEs (37) are replaced
with Arg-369 and Leu-406 in T. brucei and T. evansi and with
Arg-421 and Leu-458 in T. congolense. Furthermore, a con-
5 A. Schnaufer, personal communication. 6 S. Kunz, unpublished data.
FIGURE 3. Determination of PDEC activity by complementation of a PDE-
deficient S. cerevisiae strain. A, heat shock assay on the strains expressing
PDEC from various trypanosomatids. Left panel, control incubation without
heat shock; right panel, 15-min heat shock (55 °C) before incubating the plate
at 30 °C. HA or HA, expression constructs without or with an N-terminal
hemagglutinin tag. Both constructs are similarly effective for complementa-
tion. Negative control is the yeast strain transfected with empty vector. B,
PDEC expression in the recombinant yeast strains. Recombinant PDECs were
detected by immunoblotting with anti-hemagglutinin antibody. C, Ponceau
staining. D, kinetoplastid phylogeny derived from maximal likelihood of 18 S
ribosomal RNA (adapted from Ref. 26), confirming the split of T. vivax from
T. brucei. Gray boxes, species with inactive PDEC.
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served hydrophobic residue in class 1 PDEs (methionine, leu-
cine, or isoleucine) is replaced by either threonine (Thr-479 in
T. brucei and T. evansi) or tyrosine (Tyr0531 in T. congolense).
Because these residues are critical for binding of the metal ion
and substrate, the mutations would presumably inactivate the
PDEs. To verify this prediction, the PDECs of T. brucei and
T. congolense (predicted to be inactive) and ofT. vivax,T. cruzi,
and L. major (predicted to be active) were expressed in a PDE-
deficient strain of S. cerevisiae. Complementation of PDE-defi-
cient S. cerevisiae restores its heat shock resistance and repre-
sents a very sensitive assay for cAMP-PDE activity (25). As
predicted by sequence analysis, the PDECs ofT. cruzi, L. major,
and T. vivax were catalytically active and able to complement
the PDE deficiency (Fig. 3A). In contrast, the PDEC of neither
T. brucei nor T. congolense was active in this assay (Fig. 3A),
although the expression of their recombinant proteins was
ascertained by immunoblotting (Fig. 3, B and C). Phylogenetic
analysis demonstrated that the mutational inactivation of
PDEC occurred rather late in the evolution of the trypano-
somes, after the separation of the T. brucei/T. congolense/
T. evansi clade from the remainder of the trypanosomatids (Fig.
3D) (38).
The fact that the open reading frames of TbrPDEC,
TviPDEC, and TevPDEC encode full-length but catalytically
inactive proteins implies that these proteins play a role unre-
lated to their PDE activity. To determine whether inactive
PDECs are expressed, transcription of PDEC was studied in
T. brucei. Deep sequencing of mRNAs of various stages of the
T. brucei life cycle (39) revealed that stable transcripts of the
TbrPDECgene (Tb927.3.3070) are present in all life cycle stages
and that they are processed at onemajor and a fewminor splice
sites. The overall abundance of TbrPDEC transcripts in T. bru-
cei (50/106 total transcripts) is not significantly different
between different life cycle stages (bloodstream versus procy-
clic forms). It is also similar to that of the enzymatically active
TcrPDEC of T. cruzi (30/106 total transcripts).7,8 Northern
blot analysis indicates a transient 2-fold increase in mRNA lev-
els during transformation frombloodstream toprocyclic forms,
in agreement with a recent microarray analysis that demon-
strated a similar up-regulation of Tb927.3.3070 during differ-
entiation from short stumpy to procyclic forms (40). The
expression of the TbrPDEC protein has also been established in
a proteomics approach with procyclic T. brucei (41) (the older
designation Tb03.27C5.640 was used in this work).
Kinetics of TcrPDEC1 Catalytic Domain—Two alleles of
TcrPDEC from T. cruzi have been sequenced and were shown
to vary in 35 of 924 amino acids. The TcrPDEC1 catalytic
domain (residues 270–614) hydrolyzes cAMPwith aKm of 23.8
Mand a kcat of 31 s1 and cGMPwith aKmof 99.1Mand a kcat
of 17 s1. The catalytic efficiency kcat/Km is 1.3 and 0.18 s1
M1, respectively, for cAMP and cGMP and indicates the dual
specificity of TcrPDEC1with7-fold preference of cAMPover
cGMP (Table 2). These enzymatic parameters are consistent
with the Km values of 31.6 and 78.2 M for cAMP and cGMP,
which were reported earlier for full-length TcrPDEC1 (13). It is
interesting to note that the kcat of the TcrPDEC1 catalytic
domain is 7.5–90 times the kcat values of other reported PDEs,
although the catalytic efficacy of TcrPDEC1 is still comparable
with other PDEs because of its weak apparent association con-
stant (Table 2).
The potency of various inhibitors of human PDEs was
assayed against full-length TcrPDEC1 (Fig. 4 and Table 3). It
was found that some inhibitors such as etazolate and trequinsin
are very potent (Table 3 for IC50 values), and thus their scaffolds
might be taken as starting models for the design of TcrPDEC
selective inhibitors.
Structure of TcrPDEC1Catalytic Domain—The structures of
the unliganded TcrPDEC1 catalytic domain (traceable residues
277–609) and its complex with inhibitor wyq16 were deter-
mined at medium resolution (Table 1). The crystallographic
asymmetric unit contains eight molecules that are associated
into an octamer or two tetramers (Fig. 5, A and B). The oligo-
merization of the TcrPDEC1 catalytic domain is different from
those of human PDEs and LmjPDEB1 (42, 43). It is not clear
whether the tight tetrameric or octameric association of the
TcrPDEC1 catalytic domain is biologically relevant.
Amonomer of the TcrPDEC1 catalytic domain comprises 16
-helices with two divalent metal ions bound at the bottom of
the active site (Fig. 5, C and D). The -helices are arranged in a
similar topology as those of the catalytic domains of human
PDEs and LmjPDEB1 (42, 43). The nature of the divalent metal
ions was not identified, but zinc and magnesium were used in
the structure refinement, as it has been done in the structures of
human PDEs (42). Themetal ion assignment appears to be rea-
sonable and is supported by the comparable B-factors of the
metal ions with the protein residues (Table 1) and proper elec-
tron density in the unbiased maps of (Fo  Fc) and (2Fo  Fc).
7 K. Gunasekera, personal communication.
8 T. Ochsenreiter, personal communication.
TABLE 2
Kinetic parameters of PDEs
The kinetics data of LmjPDEB1 and human PDEs are cited from Refs. 28, 43, 45, 52, and 53. ND, not determined.
cAMP cGMP
Km kcat kcat/Km Km kcat kcat/Km
M s1 s1M1 M s1 s1M1
TcrPDEC (270–614) 21.3 	 2.1 30.7 	 0.9 1.4 	 0.1 87.0 	 6.2 16.7 	 0.4 0.19 	 0.02
LmjPDEB1 (582–940) 20.6 	 3.4 2.7 	 0.3 0.13 	 0.01 1000 ND ND
PDE4D2 1.5 	 0.2 3.9 	 0.3 2.7 	 0.4 990 	 100 5.2 	 0.8 0.053 	 0.008
PDE5A1 (535–860) ND ND ND 5.1 	 1.3 1.3 	 0.3 0.27 	 0.08
PDE7A1 (130–482) 0.20 	 0.03 1.6 	 0.2 7.9 	 0.9 3900 	 700 6.8 	 1.3 0.0018 	 0.0001
PDE8A1 (480–820) 1.8 	 0.1 4.0 	 0.1 2.2 	 0.1 1600 	 100 1.6 	 0.2 0.001 	 0.0001
PDE10A2 (449–789) 0.056 	 0.005 0.33 	 0.02 5.9 	 0.6 4.4 	 0.3 1.2 	 0.1 0.27 	 0.01
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The zinc ion chelates withHis-372, His-409, Asp-410, andAsp-
521, plus two water molecules in an octahedral configuration.
The magnesium ion coordinates with Asp-410 and five water
molecules to form an octahedron. An unexpected observation
of this study is that the N-terminal fragment of TcrPDEC1
stretches from the back to the front of the molecule and
approaches the substrate-binding pocket of the enzyme (Fig. 5,
C and D). This observation implies that the N terminus might
play a role in regulation of the enzymatic activity of TcrPDEC1
via a direct interaction with the active site. This argument is
consistent with the report that a fragment of the upstream con-
served region of human PDE4 interacts with the inhibitors at
the active site (44). However, the corresponding loop of PDE4,
which links the upstream conserved region fragment to the
back of the PDE4 domain, is disordered, in contrast to the
observable conformation of our N-terminal stretch.
Structural superposition of the TcrPDEC1-wyq16 complex
over human PDE4D, human PDE5A, and LmjPDEB1 yielded
RMS deviations of 1.45, 1.38, and 1.59 Å for the C atoms of
269, 287, and 247 comparable residues, respectively (Fig. 5, E
and F), indicating their overall similarity. However, there are
some subtle but significant differences between them.
TcrPDEC1 lacks the short helixH4 but has an extra helix before
H7. The long helix H14 is split into two helices in TcrPDEC1
because of a missing amino acid before Val-537. The biological
meaning of these differences is not clear but might simply
reflect the consequence of the amino acid sequence variation.
Themost significant change is associated with theM-loop (res-
idues 544–564) at the active sites of the PDEs, which showed
differences of several Angstroms between their C atoms (Fig.
5, B, E, and F). These conformational changes do not appear to
result from inhibitor binding, as shown by the comparable con-
formations and positions of the M-loops between the unligan-
ded and wyq16-bound structures. However, it is not clear
whether the M-loop changes represent the native conforma-
tion differences between TcrPDEC and other PDEs or the con-
sequence of the crystal packing because some residues of the
M-loop such as Pro-558 and Glu-561 are involved in formation
of the tetramer in the crystal (Fig. 5B). On the other hand, the
H-loop at the active site of TcrPDEC favorably compares with
that of human PDE4 but not PDE5. Because most human PDE
families have an H-loop conformation similar to PDE4 and
PDE5 uniquely shows multiple conformations (42, 45, 46), the
H-loop might not be an attractive target for the design of
TcrPDEC inhibitors.
Inhibitor Binding—The PDE5 inhibitor wyq16 (Fig. 2) shares
the ethoxyphenyl and pyrazolopyrimidinone groups with silde-
FIGURE 4. Potency of human PDE inhibitors against TcrPDEC1. Com-
pounds were tested at 100 M against full-length recombinant TcrPDEC1.
TABLE 3
Potency of human PDE inhibitors against TcrPDEC
¶ IBMX, 3-isobutyl-1-methylxanthine.
* EHNA, erythro-9-(2-hydroxy-3-nonyl)-adenosine.
# The IC50 values of these compounds were measured by using the TcrPDEC1
catalytic domain.
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nafil but differs in an isopropyloxycarbonylamino group from
N-methylpiperazinyl. wyq16 inhibits the catalytic activities of
PDE5A and TcrPDEC1 with IC50 values of 3.2 and 230 nM,
respectively. The electron density maps clearly define the con-
formation and position of the ethoxyphenyl and pyrazolopy-
rimidinone groups of wyq16 (supplemental Fig. S3). However,
FIGURE 5. The structure of the TcrPDEC1 catalytic domain. A, ribbon diagram of octamer of the TcrPDEC1 catalytic domain. B, ribbon of tetrameric TcrPDEC1.
C, ribbon of TcrPDEC1 monomer. The inhibitor wyq16 is presented as the ball and stick model. The red coil represents the long N-terminal fragment that
stretches from the back to the front of the molecule and approaches the active site. D, surface presentation of the TcrPDEC1 catalytic domain, in a view of 100o
rotation around the vertical axis of C. The balls represent the long N-terminal fragment that stretches around the domain. E, superposition between the catalytic
domains of TcrPDEC1 (cyan) and human PDE4D2 (yellow). F, superposition between TcrPDEC1 (cyan) and human PDE5A1 (light purple). The figure shows that
the M-loops have significant conformational differences.
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the isopropyloxycarbonylamino tail seems more flexible, as
shown by the weaker density and higher B-factors. wyq16 binds
to theTcrPDEC1 active site with two conserved characteristics:
the NE2 atom of the invariant Gln-570 forms a hydrogen bond
with O1 of wyq16, and Phe-573 stacks against the pyrazolopy-
rimidinone ring of wyq16 (Fig. 6). In addition, wyq16 forms van
der Waals contacts with residues Tyr-367, Thr-417, Met-482,
Leu-496, Ile-538, Phe-542, Phe-560, Ser-569, and Phe-577. An
unexpected finding is that the common pyrazolopyrimidinone
rings of wyq16 and sildenafil orient oppositely. As a result, the
hydrogen bonding patterns are completely different, although
the pyrazolopyrimidinone rings of bothmolecules stack against
the phenylalanine (Phe-573 in TcrPDEC1). The side chain of
the invariant glutamine forms two hydrogen bonds with the
pyrazolopyrimidinone ring of sildenafil in PDE5A (45), but only
one with wyq16 (Fig. 6B). This difference might be due to the
different conformations of the invariant glutamine, in which
the glutamine side chain of TcrPDEC1 has an opposite orien-
tation to that of PDE5 (Fig. 6) but the same as that of PDE4.
Potential Parasite Pocket—Our earlier work revealed that
LmjPDEB1 has a small pocket neighboring the active site (orig-
inally designated as the L-pocket) (43). The TcrPDEC1 struc-
tures further showed that the pocket is unique and universal for
the kinetoplastid PDEs, and thus the term “P-pocket” appears
FIGURE 6. Binding of inhibitor wyq16. A, wyq16 binding to the active site of TcrPDEC1. The dotted lines represent hydrogen bonds. The TcrPDEC1 and PDE5A
residues are presented as yellow and light blue sticks, respectively. B, superposition of wyq16 (green sticks) over sildenafil (gray). The invariant glutamine
(Gln-570 of TcrPDEC1 and Gln-817 of PDE5A) have different orientations of their side chains. The light blue nets represent the (Fo  Fc) electron density that was
calculated from the TcrPDEC1 structure with omission of wyq16 and contoured at 2.0.
FIGURE 7. The parasite pocket (P-pocket). A, P-pocket of TcrPDEC1 with bound wyq16. Residues Glt-559 and Ser-569 of TcrPDEC1 are gatekeepers.
B, sequence alignment of the corresponding pocket regions in trypanosome, leishmania, and human PDEs. Two gatekeeper residues (blue) isolate the P-pocket
from the active sites in human PDE families.
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to be more appropriate. The P-pocket is made up of residues
from the M-loop and helix H14, including Leu-539, Ala-543,
Gly-559, Ser-564, Val-566, and Ser-569 of TcrPDEC1 (Fig. 7A).
Two key residues, Gly-559 and Ser-569, serve as the gatekeep-
ers guarding the access to the P-pocket. In most other kineto-
plastid PDE families, the residues corresponding to Gly-559
and Ser-569 are methionine/phenylalanine and glycine (Fig.
7B). Therefore, the gate to the P-pocket of all the kinetoplastid
PDEs is sterically open and accessible. However, in human
PDEs, this pocket is either blocked by two large gating residues
or disappears because of variations in sequence, as shownby the
sequence alignment (Fig. 7B). Thus, the P-pocket might be an
invaluable structural element for developing parasite-specific
PDE inhibitors.
Hint on Use of Some Human PDE Inhibitors as Starting Scaf-
folds for Design of Parasite PDE Inhibitors—The kinetic and
structural studies imply that certain inhibitors of human PDEs
could be used as the starting framework for the design of para-
site-selective inhibitors. This argument is supportedby the inhib-
itory effects of some human PDE inhibitors on TcrPDEC (Fig. 4
and Table 3). For example, etazolate inhibits human PDE4 and
TcrPDECwith the IC50 valuesof 2 and0.7M, respectively, for the
full-lengthenzymes (13) andof1.1 and0.3Mfor thePDE4D2and
TcrPDEC catalytic domains. Moreover, the pyrazolopyrimidi-
none ring of wyq16 binds to TcrPDEC in an opposite orientation
to the same ring of sildenafil in PDE5A (45). Although the IC50 of
wyq16 is only 230 nM, the pyrazolopyrimidinone ring might be
used as a potential starting scaffold for TcrPDEC inhibitors
because of the opposite orientations of both the nine-membered
ring and the side chain of the invariant glutamine. Finally, the
structure shows that the pyzarole of wyq16 points toward the
P-pocket. A suitable substitution on the pyzarole ring would
extend the inhibitors to the P-pocket andmay thus improve their
affinity and selectivity.
Implication of Inactive Parasite PDECs—The finding that
mutations during the course of evolution inactivated the
PDECs of T. brucei, T. evansi, and T. congolense, has come as a
surprise. Interestingly, such a case has also been reported for
other enzymes of eukaryotes, including protein kinases (47),
protein phosphatases (48), and proteases (49). For example, the
EGF receptor kinase HER3 ismutationally locked in an inactive
conformation, despite the fact that it can still bind ATP and
coordinate Mg2. However, HER3, rather than serving as a
kinase, plays an important role in controlling the activity of
other EGF receptors upon ligand binding (50). In another
example, inactive homologs of the rhomboid membrane pro-
teases play an important role in controlling the activity of the
active enzymes (49).
A systematic survey of metazoan enzymes has identified
many inactive forms of other enzymes, but PDE homologs (51).
Thus, the kinetoplastid PDECs represent the first case of a PDE
family, in which active and inactive homologs coexist and are
stably expressed. The inactive TbrPDEC gene is regulated and
expressed inT. brucei at similar levels as the active TcrPDEC in
T. cruzi, suggesting that the inactive PDECs may still fulfill a
cellular function unrelated to cyclic nucleotide hydrolytic activ-
ity. Nevertheless, the function of the active enzyme in species of
L. major and T. cruzi remains to be established in detail. Of
equal interest will be the elucidation of whethermaintenance of
the inactive PDECs in T. brucei, T. congolense, and T. evansi is
due to a selective pressure exerted by their life style.
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36. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P.,
Grosse-Kunstleve, R.W., Jiang, J. S., Kuszewski, J., Nilges,M., Pannu,N. S.,
Read, R. J., Rice, L.M., Simonson, T.,Warren, G. L. (1998) Crystallography
& NMR system. A new software suite for macromolecular structure de-
termination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921
37. Beavo J. A., Francis, S. H., and Houslay, M. D. (2006) in Cyclic Nucleotide
Phosphodiesterases in Health and Disease (Beavo, J. A., Francis, S. H., and
Houslay, M. D., eds) CRC Press, Boca Raton, FL
38. Stevens, J., and Rambaut, A. (2001) Evolutionary rate differences in
trypanosomes. Infect. Genet. Evol. 1, 143–150
39. Nilsson, D., Gunasekera, K., Mani, J., Osteras, M., Farinelli, L., Baerlocher,
L., Roditi, I., and Ochsenreiter, T. (2010) Spliced leader trapping reveals
widespread alternative splicing patterns in the highly dynamic transcrip-
tome of Trypanosoma brucei. PLoS Pathog. 6, e1001037
40. Kabani, S., Fenn, K., Ross, A., Ivens, A., Smith, T. K., Ghazal, P., and
Matthews, K. (2009) Genome-wide expression profiling of in vivo-derived
bloodstream parasite stages and dynamic analysis of mRNA alterations
during synchronous differentiation inTrypanosoma brucei.BMCGenom-
ics 10, 427
41. Jones, A., Faldas, A., Foucher, A., Hunt, E., Tait, A., Wastling, J. M., and
Turner, C.M. (2006)Visualisation and analysis of proteomic data from the
procyclic form of Trypanosoma brucei. Proteomics 6, 259–267
42. Ke, H., andWang, H. (2007) Crystal structures of phosphodiesterases and
implications on substrate specificity and inhibitor selectivity. Curr. Top.
Med. Chem. 7, 391–403
43. Wang,H., Yan, Z., Geng, J., Kunz, S., Seebeck, T., andKe,H. (2007) Crystal
structure of the Leishmania major phosphodiesterase LmjPDEB1 and in-
sight into the design of the parasite-selective inhibitors. Mol. Microbiol.
66, 1029–1038
44. Burgin, A. B., Magnusson, O. T., Singh, J., Witte, P., Staker, B. L., Bjorns-
son, J.M., Thorsteinsdottir,M., Hrafnsdottir, S., Hagen, T., Kiselyov, A. S.,
Stewart, L. J., and Gurney, M. E. (2010) Design of phosphodiesterase 4D
(PDE4D) allosteric modulators for enhancing cognition with improved
safety. Nat. Biotechnol. 28, 63–70
45. Wang, H., Liu, Y., Huai, Q., Cai, J., Zoraghi, R., Francis, S. H., Corbin, J. D.,
Robinson,H., Xin, Z., Lin, G., andKe,H. (2006)Multiple conformations of
phosphodiesterase-5. Implications for enzyme function and drug devel-
opment. J. Biol. Chem. 281, 21469–21479
46. Wang, H., Ye, M., Robinson, H., Francis S. H., and Ke, H. (2008) Confor-
mational variations of both phosphodiesterase-5 and inhibitors provide
the structural basis for the physiological effects of vardenafil and sildenafil.
Mol. Pharmacol. 73, 104–110
47. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S.
(2002) The protein kinase complement of the human genome. Science
298, 1912–1934
48. Pils, B., and Schultz, J. (2004) Evolution of the multifunctional protein
tyrosine phosphatase family.Mol. Biol. Evol. 21, 625–631
49. Zettl, M., Adrain, C., Strisovsky, K., Lastun, V., and Freeman, M. (2011)
Rhomboid family pseudoproteases use the ER quality control machinery
to regulate intercellular signaling. Cell 145, 79–91
50. Jura, N., Shan, Y., Cao, X., Shaw, D. E., and Kuriyan, J. (2009) Structural
analysis of the catalytically inactive kinase domain of the human EGF
receptor 3. Proc. Natl. Acad. Sci. U.S.A. 106, 21608–21613
51. Pils, B., and Schultz, J. (2004) Inactive enzyme-homologues find new func-
tion in regulatory processes. J. Mol. Biol. 340, 399–404
52. Wang, H., Yan, Z., Yang, S., Cai, J., Robinson, H., and Ke, H. (2008) Kinetic
and structural studies of phosphodiesterase-8A and implication on the
inhibitor selectivity. Biochemistry 47, 12760–12768
53. Wang, H., Liu, Y., Hou, J., Zheng, M., Robinson, H., and Ke, H. (2007)
Structural insight into substrate specificity of phosphodiesterase 10. Proc.
Natl. Acad. Sci. U.S.A. 104, 5782–5787
Crystal Structure of TcrPDEC1
APRIL 6, 2012 • VOLUME 287 • NUMBER 15 JOURNAL OF BIOLOGICAL CHEMISTRY 11797
